ArticleJournal of cardiovascular translational research2025
Serum Interleukin-8 Levels Identify Non-Atrial Fibrillation Patients at Risk for Catheterization-Confirmed Diastolic Dysfunction: A Retrospective Cohort Study.
Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interleukin-8 in health and disease.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular diastolic dysfunction (LVDD), confirmed by left heart catheterization, is the gold standard for diagnosing heart failure with preserved ejection fraction (HFpEF). However, current noninvasive diagnostic tools may fail to detect early-stage LVDD in patients without prior hospitalization for heart failure, delaying timely intervention. Given its role in inflammation and cardiovascular remodeling, serum interleukin-8 (IL-8) may serve as a potential biomarker for early detection. We conducted a retrospective cohort study that included patients who underwent diagnostic left heart catheterization between March 2020 and August 2024. In the discovery cohort (n = 1,014), we assessed the associations of 12 inflammatory cytokines with catheterization-confirmed LVDD via a highly sensitive flow cytometer. IL-8, the most strongly associated cytokine, was further evaluated in a separate prospective validation cohort (n = 248). Diagnostic performance was evaluated via the area under the receiver operating characteristic curve (AUC). IL-8 levels were significantly elevated in LVDD patients without atrial fibrillation compared with controls, with a 2.26-fold median increase (P < 0.001). In the discovery cohort (n = 1,014), IL-8 was independently associated with LVDD (adjusted odds ratio for highest vs. lowest quartile: 13.2 [95% CI: 6.5-26.7]). These findings were validated in an independent cohort. Combining IL-8 with B-type natriuretic peptide (BNP) and the E/e' ratio improved diagnostic accuracy, achieving an AUC of 0.79 (95% CI: 0.74-0.85). Serum IL-8 is an independent biomarker for diagnosing catheterization-confirmed LVDD in patients without atrial fibrillation. Its combination with traditional markers enhances diagnostic performance, offering a promising tool for early identification and potential risk stratification of HFpEF. Clinically, IL-8 testing may help identify patients with unexplained dyspnea who warrant closer monitoring or earlier therapeutic intervention.
Indexed as
Identifiers
41118041What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.